Axsome: IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment. The post IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. appeared first on Investor's Business Daily.
Read full article »
Axsome is a New York-based biopharmaceutical company that researches and develops novel therapies for the treatment of central nervous system disorders.
Read more